Insurers block immunoglobulin access using multiple tactics
Immunoglobulin product booklet
Xolremdi
Mavorixafor.
Approved to treat: Warts, hypogammaglobulinemia, immunodeficiency, myelokathexis (WHIM) syndrome.
Ages: 12+
Report side effects/adverse events at 1-866-MED-X4MI (1-866-633-9464).